India Glycols Q1 FY27 Results: Revenue ₹2,987 Cr, Profit ₹76.59 Cr
India Glycols reported Q1 FY27 results with standalone revenue at ₹2,987 crore and consolidated PAT at ₹96.83 crore. Standalone PAT was ₹76.59 crore. EPS stood at ₹11.43. The company is proceeding with its demerger scheme, which has received NCLT sanction.
The financial results show a stable performance. The ongoing corporate restructuring (demerger) could have a medium-term impact on the company's structure and future operations.
The company reported positive financial results with growth in revenue and profit compared to the previous year's quarter. The update on the demerger scheme also indicates forward-looking strategic moves.
India Glycols Limited announced its Unaudited Financial Results for the first quarter ended June 30, 2026, during a Board Meeting held on August 12, 2026.
The company reported total income of ₹2,987.30 crore (standalone) and ₹2,988.82 crore (consolidated) for the quarter. Expenses stood at ₹2,884.66 crore (standalone) and ₹2,886.54 crore (consolidated).
Profit After Tax (PAT) for the quarter was ₹76.59 crore on a standalone basis and ₹96.83 crore on a consolidated basis. Earnings per share (EPS) were ₹11.43 for both basic and diluted calculations on a standalone basis.
Segment-wise, for the standalone results, Bio-based Specialities and Performance Chemicals contributed ₹361.73 crore to revenue, Potable Spirits ₹2,218.67 crore, Ennature Biopharma ₹83.30 crore, and Bio-Fuel ₹323.22 crore. The profit before interest and tax (EBIT) for these segments were ₹31.75 crore, ₹75.03 crore, ₹7.25 crore, and ₹27.03 crore, respectively.
The company also provided updates on its ongoing Scheme of Arrangement, involving the demerger of its Bio Pharma undertaking into Ennature Bio Pharma Limited and its Spirits & Biofuel Undertaking into IGL Spirits Limited. The NCLT sanctioned the scheme on July 17, 2026, and the company is awaiting the certified true copy of the order. This scheme does not impact the financial results.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.